Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications CAR T Cells G-Rex®10

Publication Date: November 13, 2019

Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality

Inserting a CAR into the TRAC gene and IL-12P70 into the IL2Rα or PDCD1 genes makes CAR T cells secrete IL-12P70 transiently and in proportion to tumor-cell engagement. Using TALEN and AAV6 repair templates, over 90% of cells lacked TCRαβ and up to 65% were CAR-positive TCRαβ-negative cells. Medians of 49 and 23 pg/mL per 12 hours of IL-12P70 were secreted from the IL2Rα and PDCD1 loci, respectively, and secretion plateaued at a 1-to-1 tumor-to-T-cell ratio. Targeted cells showed low IL-12P70 before and after tumor challenge, whereas an NFAT-driven lentiviral construct leaked. IL-12P70 secretion sped tumor clearance in vitro, raised CD8+ CAR T-cell expansion in serial killing assays, and…

Download Now →

Author: Mohit Sachdeva, Brian W. Busser +10 more

Publications CAR T Cells G-Rex®100M-CS, G-Rex®24 Well Plate, G-Rex®6 Well Plate, G-Rex®6M Well Plate

Publication Date: November 10, 2019

Methods and Process Optimization for Large-Scale CAR T Expansion Using the G-Rex® Cell Culture Platform

The G-Rex® platform allows CAR T cells to be expanded in a static, gas-permeable-membrane bioreactor without media exchanges, and a process developed in small plates scales linearly to closed large-scale devices. The chapter describes a stepwise route. Maximum cell density is first established in G-Rex® 6-well or 24-well plates, with 40 mL and 5 × 10^6 cells per 6-well well. Seeding density and cytokine timing are then optimized in G-Rex®6M plates at 100 mL per well, with glucose and lactate serving as surrogates for cell number. The process is then transferred to the G-Rex®100M-CS, seeded with 50 million transduced T cells in 1 L of medium, which typically yields 3 billion cells in 9 or…

Download Now →

Author: Josh Ludwig, Mark Hirschel

Publications TIL Cells

Publication Date: November 6, 2019

Iovance Gen 2 TIL Manufacturing Process Produces Drug Products that Exhibit Favorable Quality Attributes for Adoptive Cell Transfer Across 5 Solid Tumor Indications

The Iovance Gen 2 tumor-infiltrating lymphocyte manufacturing process, used to make lifileucel for melanoma, also produced cryopreserved drug products with comparable quality attributes from other solid tumor types. Clinical-scale replicates comprised 64 melanoma, 25 cervical carcinoma, 10 head and neck squamous cell carcinoma, 3 soft tissue sarcoma and 3 non-small cell lung cancer runs. Success was defined as manufacturing starts yielding product that met release specifications. Mean viable cell dose and viability were highly comparable to lifileucel, against release specifications of at least 1 × 10^9 viable cells and 70% viability. Products were high-purity T-cell cultures defined as C…

Download Now →

Author: Seth Wardell, Maritza Lienlaf-Moreno +5 more

Publications Other

Publication Date: November 4, 2019

Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells

A defined, GMP-grade medium called Cellquin supported pure erythroid cultures from adult peripheral blood mononuclear cells without prior CD34 isolation and gave more than 90% enucleated red blood cells. Erythroblasts expanded about 3 × 10^7-fold in 25 days, and 100 million PBMC can yield 2 to 4 mL of packed red cells. Cultures started in dishes for about 7 days, then expanded in dishes or a G-Rex® bioreactor and differentiated for 12 days, with enucleation above 90% in dishes and almost 85% in G-Rex®. The cultured cells expressed mainly adult hemoglobin, matched donor blood group antigens, and showed deformability comparable to late peripheral blood reticulocytes. Daily RNA-sequencing du…

Download Now →

Author: Steven Heshusius, Esther Heideveld +9 more

Publications NK Cells

Publication Date: October 17, 2019

Membrane bound IL-21 based NK cell feeder cells drive robust expansion and metabolic activation of NK cells

A new feeder cell line, NKF, made by engineering OCI-AML3 leukemia cells to express membrane-bound IL-21, drives sustained expansion of highly cytotoxic NK cells from healthy donors. NK cells isolated from blood were co-cultured with irradiated NKF cells added weekly at a 5:1 ratio with 200 U/mL IL-2, giving about 94% CD56+/CD3− purity after two weeks, and expansion averaged 10,973-fold at five weeks. Expanded cells killed hematologic and solid tumor lines more effectively than IL-2-activated NK cells, reduced sarcoma growth and lung metastasis in mice, and extended survival in a Jurkat leukemia model by about 13 days. Mechanistically, mbIL-21 raised pSTAT3 and c-myc and increased glycoly…

Download Now →

Author: Evelyn O. Ojo, Ashish Arunkumar Sharma +10 more

Publications TIL Cells G-Rex®10

Publication Date: October 10, 2019

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

In this preclinical study, tumor-infiltrating lymphocytes (TIL) from high-grade serous ovarian cancer were expanded with IL-2 plus an agonistic 4-1BB antibody (Urelumab) and anti-CD3 (OKT3), a method the authors call TIL 3.0. Tumors from 98 resected patients were studied; in the TIL 3.0 condition, five fragments were cultured in a G-Rex® 10 flask with 20 mL medium, whereas the comparator conditions used 24-well plates. Culture success rose from 41% (22/54) with IL-2 alone and 76% (42/55) with IL-2 plus 4-1BB to 95% (41/43) with TIL 3.0, which yielded a mean of 200 × 10^6 TIL in 2–3 weeks instead of 3–5 weeks, with 80% CD8+ TIL. Sorted CD8+ TIL showed HLA-restricted IFN-γ reactivity agains…

Download Now →

Author: Donastas Sakellariou-Thompson, Marie-Andrée Forget +6 more

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: September 30, 2019

Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations

A 9-day protocol transduces and expands rhesus macaque PBMCs into CAR-T cells that keep a mainly central memory phenotype. PBMCs are activated for 2 days on anti-CD3 plates, transduced once with a gammaretroviral CD4-MBL CAR/CXCR5 vector on RetroNectin, then expanded 4 days in G-Rex® 6-well plates. Across animals, cells expanded a median 11.5-fold during the 4-day expansion, with median viability of 87.5% at day 9. Mean CAR/CXCR5 co-expression was 46.0% on day 9, and the transduced subset was on average 67.5% CD28+CD95+ central memory cells. Starting from 50–100 × 10^6 cells, the process yields enough cells for 1–2 × 10^8 cells/kg in a 10 kg rhesus macaque. Cells from antiretroviral-treat…

Download Now →

Author: Mary S. Pampusch, Kumudhini Preethi Haran +6 more

Publications TIL Cells G-Rex®10, G-Rex®100M, G-Rex®100M-CS, G-Rex®500M, G-Rex®500M-CS

Publication Date: September 24, 2019

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

This patent describes a shortened tumor-infiltrating lymphocyte manufacturing method, called Process 2A, that is completed in about 22 days compared with 43 to 55 days for the earlier Process 1C. Tumor fragments are cultured for 11 days in a single G-Rex® flask, and the resulting TIL move directly into rapid expansion for 11 days without a freeze and test step, in a closed workflow. Process 2A also uses 40 fragments per flask instead of 4, reducing the number of culture vessels and handling steps. Harvest uses the automated LOVO cell washer, and the product is cryopreserved in aliquots. Side-by-side comparisons of 1C and 2A cells covered cell counts, exhaustion markers, interferon-gamma r…

Download Now →

Author: Seth Wardell, James Bender +1 more

Publications VST Cells G-Rex®100M, G-Rex®5M

Publication Date: September 3, 2019

“Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients

A bank of cytomegalovirus-specific T cells (CMVSTs) made from only eight CMV-seropositive donors supplied an HLA-matched product to nearly all transplant recipients screened and produced virologic responses in all ten patients treated. Donors were selected by modelling the HLA types of 666 transplant recipients. Each line was expanded over 20 days, with a mean fold expansion of 102. Of 29 patients screened, 28 (96.6%) had a line sharing at least 2 HLA antigens. In this phase 1 trial, ten patients with persistent CMV infection had 7 complete and 3 partial responses by week 6 (100%; 95% CI 69.2-100.0). No graft-versus-host disease, graft failure or cytokine release syndrome occurred. Materi…

Download Now →

Author: Ifigeneia Tzannou, Ayumi Watanabe +12 more

Publications T-Cells

Publication Date: August 7, 2019

Large-scale expansion and characterization of CD3+ T-cells in the Quantum® Cell Expansion System

The Quantum Cell Expansion System, a closed automated hollow-fiber bioreactor, expanded CD3+ T cells from healthy-donor leukapheresis products to clinically relevant numbers in 8 to 9 days. Mononuclear cells from five donors were activated with anti-CD3/CD28 Dynabeads and cultured in xeno-free, serum-free medium with 100 IU/mL IL-2. Seeding 30 × 10^6 cells gave a mean of 14.8 × 10^9 cells, and seeding 85 × 10^6 gave 25.1 × 10^9 cells, with viabilities of 90% or higher. Mean CD3+ fold expansion was 1311 and 762, respectively, and doubling times were close to 20 hours. Harvested cells secreted IFN-γ, IL-2 and TNF-α after restimulation, had naïve and central memory phenotypes, and showed low…

Download Now →

Author: Claire Coeshott, Boah Vang +2 more

Publications CAR T Cells

Publication Date: July 8, 2019

RELY-30: Phase I Study of Relapsed CD30 Expressing Lymphoma Treated with CD30 CAR T Cells

This phase I protocol evaluates the safety of a single infusion of autologous T cells expressing a CD30-specific CAR with a CD28 endodomain, given after lymphodepleting chemotherapy to patients with relapsed or refractory CD30-positive Hodgkin or non-Hodgkin lymphoma. Three dose levels are escalated with a modified continual reassessment method, enrolling three to six patients per level and up to 18 patients in the escalation stage. An expansion cohort at the maximum tolerated dose allows up to 12 patients in each of four disease settings, with a total study maximum of 66. In the preceding study, nine patients were infused, none developed cytokine release syndrome, and manufacture yielded…

Download Now →

Author: Carlos Ramos, Helen E. Heslop +10 more

Publications CAR T Cells

Publication Date: July 6, 2019

Overcoming Challenges in Process Development of Cellular Therapies

CAR T cell manufacturing runs over 7 to 11 days through enrichment, stimulation, transduction and expansion, and each step carries choices that affect product quality and comparability. Patient apheresis material varies, so processes built only on healthy-donor cells may underperform; anti-CD4/CD8 microbead selection suits patients with many blasts or NK cells. Stimulation with OKT3 plus IL-2 gave a 4.2-fold mean expansion at 7 days, whereas bead-based stimulation gave about 20–30-fold for CD22 CAR T cells but reportedly a more differentiated phenotype. Expansion platforms include gas-permeable bags, G-Rex® devices, the Xuri system and the Prodigy, which at NIH yielded about 2 × 10^9 T ce…

Download Now →

Author: Steven L. Highfill, David F. Stroncek